Abstract 336P
Background
The population of Ukraine was formed as a result of several millennia of migration and medley of races. This, in turn, formed a great genetic diversity of the population living in Ukraine today. The objective of our research is to study the most common hereditary genetic disorders associated with the syndrome of familial breast cancer (hereinafter referred to as BC) and ovarian cancer (hereinafter referred to as OC) in the population of Ukrainian women.
Methods
All studies were carried out by the next-generation sequencing method (hereinafter - NGS) on the Thermo Fisher Ion Torrent Proton sequencer. For libraries preparation, Thermo Fisher Ion Chef and CleanPlex® Hereditary Cancer Panel v2 reagents were used.
Results
In order to achieve the objective, for the first time a large-scale study was conducted for the population of women in Ukraine the cohort of which included more than 1,032 patients from different regions of the country who had indications for genetic testing (BC and/or OC and/or positive family history). Blood and/or saliva were taken as biological material. In the course of the study, we identified 213 Pathogenic / Likely pathogenic variants (PV/LPV) (single nucleotide polymorphisms (SNP), deletions, duplications) in 205 samples. In percentage terms, samples with PV/LPV make up 19.9% of the total number of performed studies. Most PV/LPV were identified in the BRCA1 gene where the c.5266dup (p.Gln1756fs) variant was dominant. The second most frequently identified PV/LPV is in the CHEK2 gene where the dominant variant is c.470T>C (p.Ile157Thr). The third gene in terms of the number of PV/LPV found is BRCA2, with the predominant variant being c.475+1G>T. Genetic defects were also found in the following genes: BARD1, PALB2, TP53, ATM, NBN, BLM, MRE11, MSH2 and XRCC2.
Conclusions
Our results of the assessment of genetic disorders in BRCA1 and BRCA2 genes are quite foreseeable for the population of patients with a personal and/or family history of breast or ovarian cancer. However, it should be noted that the frequency of mutations in the CHEK2 gene is quite high and the frequency of mutations in the PALB2 gene is relatively low compared to studies in other populations in the world.
Clinical trial identification
Editorial acknowledgement
We would like to thank LifeCode Laboratories for the information provided and the opportunity to conduct the study.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
269P - Her2-low/HRR proficient early triple negative breast cancer is characterized by good prognosis
Presenter: Benedetta Pellegrino
Session: Poster session 14
270P - Dissecting molecular heterogeneity of luminal breast cancers using an ion mobility DIA proteomic approach
Presenter: Anne Patsouris
Session: Poster session 14
271P - Overall expression of human endogenous retroviruses in early breast cancer and their correlation with immunogenicity
Presenter: Julie Lecuelle
Session: Poster session 14
272P - Modulation of systemic and intratumor metabolism predicts response to fasting-mimicking diet plus chemotherapy in patients with early TNBC
Presenter: Francesca Ligorio
Session: Poster session 14
274P - A multiomic approach for camizestrant-induced estrogen receptor (ER) degradation, antagonism and anti-proliferation: Exploratory analysis from SERENA-3
Presenter: Giorgi Dzagnidze
Session: Poster session 14
275P - Phase II study of pyrotinib plus albumin-bound paclitaxel and trastuzumab (HLX02) as neoadjuvant treatment in HER2-positive, stage II-III breast cancer
Presenter: Ting Luo
Session: Poster session 14
276P - SHR-A1811 in combination with pyrotinib as neoadjuvant treatment for HER2-positive breast cancer (HER2+ BC): Preliminary results from MUKDEN 07
Presenter: Cai Liu
Session: Poster session 14
277P - Long term follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of trastuzumab in patients with HER2-positive breast cancer
Presenter: Jinmei Zhou
Session: Poster session 14
Resources:
Abstract
278P - Prognostic and biologic significance of HER2-low early-stage breast cancer with long-term follow-up
Presenter: Yuka Niwa
Session: Poster session 14
280P - Personalized treatment approaches with HER2DX in early HER2-positive breast cancer: A precision tool for treatment decision-making
Presenter: Marta Tapia Céspedes
Session: Poster session 14